Keyword: Johnson & Johnson
J&J has joined AbbVie as a partner for Morphic and its small-molecule integrin platform, pledging up to $725 million to the cause.
Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.
The funding will advance Vor's lead asset, an engineered hematopoietic stem cell therapy for acute myeloid leukemia.
Johnson & Johnson is diving deeper into robotic surgery with a $3.4 billion deal for Auris Health, designer of endoscopes aimed at lung cancer.
The panel’s decision to back the ketamine-like drug tees J&J up to win approval for one of the most notable antidepressants in decades.
J&J’s new antidepressant esketamine comes in front of an FDA advisory committee tomorrow, hoping to end a drought in novel therapies for the disorder.
Johnson & Johnson is in talks to settle most of the consumer suits against its DePuy unit over metal-on-metal hip replacements, according to reports.
J&J Vision launched a new intraocular lens for cataract treatment in Europe, designed to provide vision at both intermediate and far distances.
Janssen will have the rights to market treatments for achromatopsia and X-linked retinitis pigmentosa and the option to license more programs.
Johnson & Johnson Innovation joined a medical device incubator backed by Deerfield while making an investment of its own through J&J’s venture arm.